Pfizer Inc. (NYSE:PFE) was trading at around $27 on October 5, down 1.35% on the day and up 5.18% over twelve months.
The shares yield 6.19%. The company paid out 226.32% of its earnings to do it. Those two facts have to be reconciled before anything else about this stock matters.
READ ALSO: What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?
The Dividend Is Covered by Cash, Not Earnings:
A payout ratio above two hundred percent normally means a cut is coming. The reason it does not here is which number it is measured against. Pfizer earned $4.34 billion over the past twelve months and generated $12.49 billion of free cash flow. Dividends are paid from the second figure.
So the ratio is describing depressed earnings rather than missing money, and the margins show what depresses them. Operating margin is 27.88%. Net margin is 6.80%.
Twenty-one points disappear between those two lines, which means the costs doing the damage sit below the operating line rather than inside the business. Amortization of acquired drugs and interest on the debt that bought them account for the distance.
Neither leaves the building as cash in the year it is booked. That single fact reconciles a 226.32% payout ratio with a dividend nobody expects to be cut. The market reads it the same way, pricing the shares at 9.67 times forward earnings against 37.08 times trailing.
DON’T MISS: Here is Why Tripadvisor (TRIP) is a Bad Investment at Today’s Price
The Problem Is What Happens After the Patents:
The case against is not the dividend. It is what replaces the drugs currently paying it. Revenue grew 2.60% last quarter. For a pharmaceutical company, that is the state preceding decline, because every patent has an expiry date written into it, and flat sales mean nothing new is offsetting what is running off.
The usual fix is to buy the next generation, and the balance sheet is why that is harder here. Debt of $63.48 billion against $11.7 billion of cash lifts enterprise value to $212.11 billion against a $160.62 billion market value.
Roughly a quarter of the purchase price is borrowing taken on to buy the last round of growth.
Return on equity of 5.01% is what that looks like afterwards. A business earning a 27.88% operating margin should not return five percent on equity, and it does because the acquired asset base it sits on is so large. Flat revenue is the part no multiple fixes. Ten stocks we think are better positioned are named here.
The Valuation Case:
Sustainability is what the yield is asking about. Cash flow of $12.49 billion covers the dividend today, and whether it does in five years depends on a pipeline nobody outside the company can see.
On price, almost nothing is demanding. At 9.67 times forward earnings and 1.89 times book value, the market pays very little for a 27.88% operating margin. Enterprise value to EBITDA of 15.72 counts the debt, and it is the least flattering measure of the set.
A beta of 0.28 means these shares move roughly a quarter as much as the index. Not every high yielder has sat this still, and this year’s best performers are ranked here.
Conclusion:
The 226.32% payout ratio looks alarming and is not the real risk. Free cash flow of $12.49 billion against $4.34 billion of reported earnings means the dividend is funded by cash the income statement does not show. At 9.67 times forward earnings, the price asks very little. However, revenue grew 2.60%, and return on equity is 5.01%. Another $63.48 billion of debt limits the acquisitions that normally replace expiring drugs. The number to watch is free cash flow, because it is the dividend’s only real cover.
Market Sentiment:
Pfizer Inc. was held by 83 hedge funds with a combined stake value of about $4.71 billion at the end of Q2 2026 in the Insider Monkey database. This is unchanged from 83 hedge fund holders with a cumulative investment value of around $6.15 billion in the previous quarter.
READ NEXT: What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing? and Here is Why Tripadvisor (TRIP) is a Bad Investment at Today’s Price
This article is originally published at Insider Monkey.
